Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Exploring treatment resistance in myeloma with MRD

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, gives an outline of a study analyzing MRD profiling and treatment resistance in patients with standard- and high-risk myeloma, enrolled on the GEM2012MENOS65 trial (NCT01916252). MRD was evaluated using next-generation flow cytometry. Undetectable MRD after VRD (bortezomib, lenalidomide and dexamethasone) induction, transplant and VRD consolidation, was found to overcome poor prognosis in patients with high-risk cytogenetic abnormalities. Furthermore, characterization of MRD cells revealed greater clonal selection in standard-risk myeloma and greater genomic instability in high-risk patients. This interview took place during the 2021 European Myeloma Network (EMN) congress.